Semaglutide is FDA-approved for both type 2 diabetes (Ozempic, 2017) and chronic weight management (Wegovy, 2021), with extensive Phase 3 clinical trial data including the STEP program and SELECT cardiovascular outcomes trial (PMID: 37952131)
Today, many years after the first GLP-1 drug was approved, two of them---Wegovy and Saxenda--- are currently approved for weight loss with a third drug, Mounjaro about to be approved
Consistency within a few hours is ideal, but tirzepatide's 7-day action window is forgiving
Who Ozempic Is Best For Ozempic works well for individuals who: Have type 2 diabetes or prediabetes Experience intense hunger linked to blood sugar fluctuations Struggle with afternoon or evening cravings Prefer a once-weekly injection Have difficulty with emotional or stress related eating patterns Need both metabolic stabilization and appetite control Patients preparing for bariatric surgery who also have diabetes may benefit from Ozempic as part of a preoperative optimization plan
Avoid repeated freeze-thaw cycles, as they can degrade peptides
